Sikkim Journal

Oncolytic Virus Cancer Therapy Pipeline Insight, 2022 by Delveinsight

 Breaking News
  • No posts were found

Oncolytic Virus Cancer Therapy Pipeline Insight, 2022 by Delveinsight

June 20
20:12 2022
Oncolytic Virus Cancer Therapy Pipeline Insight, 2022 by Delveinsight

DelveInsight’s, Oncolytic Virus Cancer Therapy Pipeline Insight, 2022 report provides comprehensive insights about 40+ companies and 80+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

“Oncolytic Virus Cancer Therapy Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines. The assessment part of the report embraces, in depth Oncolytic virus cancer therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncolytic virus cancer therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Oncolytic Virus Cancer Therapy: An Overview

Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses.

The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.

 

Download a sample copy of the market report @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Oncolytic Virus Cancer Therapy Mechanism

The therapeutic efficacy of Oncolytic viruses depends on two main modes of action:

• Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts.

• Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigensand secreting cytokines.

 

Oncolytic Virus Cancer Therapy Emerging Drugs

CG0070: CG Oncolgy

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.

ONCOS-102: Targovax

ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.

 

Oncolytic Viruses for Cancer Treatment

Besides several advantages of Oncolytic viruses as antitumor therapy, there are still many challenges which needs to be solved. Following are few hurdles that needs to be answered for translation of these therapies:

• Choosing Optimal Oncolytic virus Species

• Efficient Oncolytic virus Delivery (Local or Systemic)

• Enhancing Intra tumoral Oncolytic virus Infiltration and Diffusion

• Anti-Viral Immunity

• Immunosuppressive tumor microenvironment

 

Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment

This segment of the report provides insights about the different Oncolytic Virus Cancer Therapy pipeline drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Oncolytic Virus Cancer Therapy

There are approx. 40+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncolgy.

 

Oncolytic Virus Cancer Therapy Pipeline: Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Oncolytic Virus Cancer Therapy Pipeline Companies

• Affinia Therapeutics

• Lacerta Therapeutics

• Lokon Pharma AB

• Merck Sharp & Dohme Corp.

• Wuhan Binhui Biotechnology

• CG oncology

• BioVex Limited

• Oncolys BioPharma Inc.

• Replimmune

• Transgene

• Sorrento therapeutics

• ORCA therapeutics

• TILT Biotherapeutics

• Bioeclipse therapeutics

• Oncolys BioPharma

• Oncorus

• DNAtrix

• OncoMyx

• Vyriad

• VCN Biosciences

• Boehringer Ingelheim

• IconOVir

• Immugene

• AbbVie

• Turnstone Biologics, and several others

 

Request a sample copy of the pipeline report- https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Table of Content

  • Introduction
  • Executive Summary
  • Oncolytic Virus Cancer Therapy: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Oncolytic Virus Cancer Therapy Collaboration Deals
  • Late Stage Products (Phase III) 
  • CG0070: CG Oncolgy
  • Mid Stage Products (Phase II)
  • ONCOS-102: Targovax
  • Early Stage Products (Phase I/II) 
  • Drug Name: Company Name
  • Inactive Products
  • Oncolytic Virus Cancer Therapy Key Companies
  • Oncolytic Virus Cancer Therapy Key Products
  • Oncolytic Virus Cancer Therapy- Unmet Needs
  • Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
  • Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
  • Oncolytic Virus Cancer Therapy Analyst Views
  • Oncolytic Virus Cancer Therapy Key Companies
  • Appendix

 

Abuot Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles